Tenet Reports Strong Fourth Quarter and FY 2024 Results; Provides 2025 Financial Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Tenet Healthcare (THC) PT Lowered to $185 at Raymond James, 'Selloff After Quarter is Perplexing — Creates Attractive Entry Point Despite Policy Risks'
February 13, 2025 8:45 AM ESTRaymond James analyst John Ransom lowered the price target on Tenet Healthcare (NYSE: THC) to $185.00 (from $195.00) while maintaining a Outperform rating.
The analyst comments "We reiterate our Outperform rating on shares of THC while lowering our price target to $185 (8.5x 2026 EBITDA ex-NCI) following 4Q24 results that were slightly... More
